Jun 21, 2022 2:00am EDT NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
Jun 03, 2022 4:05pm EDT NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
Jun 03, 2022 7:00am EDT NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
May 10, 2022 2:00am EDT NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
